Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly.
about
Clinical, quality of life, and economic value of acromegaly disease controlPharmacological treatment of acromegaly: its place in the overall therapeutic approach.Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors.Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets.Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA).Cost of clinical management of acromegaly in Spain.
P2860
Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly.
@en
Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly.
@nl
type
label
Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly.
@en
Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly.
@nl
prefLabel
Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly.
@en
Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly.
@nl
P2093
P2860
P356
P1476
Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly.
@en
P2093
Alberto M Pereira
Ferdinand Roelfsema
Johannes A Romijn
Nienke R Biermasz
P2860
P304
P356
10.1586/ERP.09.17
P577
2009-06-01T00:00:00Z